Cancer clinical trials in the region Grand Est

294 currently recruiting clinical trials
Region Grand Est

Phase 3 Lymphoma CLL & Richter's syndrome #NCT06943872 #2024-517131-52-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06428019 #2024-512147-23-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Abbvie
Phase 3 Colon cancer Rectal cancer #NCT06293625
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
57 recruiting sites
CHU Dijon
Phase 3 Lung cancer #NCT06793215 #2024-518365-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Hoffmann-La Roche
Phase 3 Lung cancer #NCT06767514
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR HER2 HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
14 recruiting sites
Summit Therapeutics
Phase 3 Liver and bile duct cancer #NCT05615818 #2023-508100-38-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
37 recruiting sites
UNICANCER
Phase 3 Prostate cancer #NCT03819101 #2023-508072-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery Hormone therapy
22 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lung cancer #NCT06077760 #2023-504923-20-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required previous treatments at advanced or metastatic stage
Surgery
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
6 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer #NCT04916613 #2022-502425-18-00
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
49 recruiting sites
UNICANCER